Anti-LMA Binding Proteins for Selective Myeloma Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aberrant proliferation of plasma cells and their precursors, such as multiple myeloma, are inadequate in providing a cure and are associated with significant morbidity and resistance to treatment.
Innovation Solution
Development of anti-lambda myeloma antigen (LMA) binding proteins that preferentially target LMA over free lambda light chains, utilizing specific CDR sequences to mediate targeted killing of LMA-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for multiple myeloma, then initial response to therapy is achieved, but treatment resistance develops and relapse occurs
Solution Approach 1:
The patent modifies the antibody structure by changing parameters of the heavy chain variable region, specifically introducing mutations in the CDR2 and CDR3 regions to alter binding affinity and specificity for LMA, thereby overcoming treatment resistance
Solution Approach 2:
The invention introduces specific local modifications to the antibody's antigen-binding site, particularly in the CDR regions, to enhance selective binding to LMA on myeloma cells while maintaining stability and reducing off-target effects
2Productivity
If existing therapies are administered, then tumor growth is initially controlled, but significant morbidity and disability occur due to treatment toxicity
Solution Approach 1:
The patent extracts and isolates the specific antigen LMA on myeloma cells as the therapeutic target, enabling selective destruction of cancer cells through anti-LMA antibodies while sparing healthy tissues from toxic effects
Solution Approach 2:
The anti-LMA binding protein acts as an intermediary that selectively delivers cytotoxic effects to LMA-expressing cells through mechanisms such as ADCP and CDC, reducing direct exposure of healthy tissues to toxic chemotherapy agents
3Measurement precision
If binding proteins are designed to target free lambda light chain, then high binding affinity is achieved, but specificity for LMA-expressing cells is reduced
Solution Approach 1:
The patent changes the binding parameters of the antibody by modifying the heavy chain CDR regions, transforming the binding preference from free lambda light chain to LMA on cell surfaces through specific amino acid substitutions
Solution Approach 2:
The invention introduces local structural modifications specifically in the CDR2 and CDR3 regions of the heavy chain variable region to create a binding interface that recognizes conformational epitopes on LMA rather than linear sequences on free light chain
Data Source
AI summary
The present disclosure relates to anti-LMA binding proteins. Such binding proteins may be useful for treating disorders associated with aberrant proliferation of plasma cells and/or their precursors.